170
Views
24
CrossRef citations to date
0
Altmetric
Original Article

Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study

&
Pages 2961-2970 | Accepted 12 Sep 2007, Published online: 15 Oct 2007

References

  • Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc 2003;289:179–86
  • Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. J Am Med Assoc 2004;292:1333–40
  • Dushoff J, Plotkin JB, Viboud C, et al. Mortality due to influenza in the United States – an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006;163:181–7
  • Sessa A, Costa B, Bamfi F, et al. The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy. Fam Pract 2001;18:629–34
  • Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000;19:834–42
  • Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998; 48:85–90
  • Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999;44(Suppl B):11–5
  • Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54:1–40
  • Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial [US Oral Neuraminidase Study Group]. J Am Med Assoc 2000;283:1016–24
  • Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667–72
  • Nordstrom BL, Sung I, Suter P, et al. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin 2005;21:761–8
  • Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial [Neuraminidase Inhibitor Flu Treatment Investigator Group]. Lancet 2000;355:1845–50
  • Bettis R, Iacuzio D, Jung T, et al. Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Invest 2006;26:329–40
  • Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970–78. Am J Public Health 1986;76:761–5
  • Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. J Am Med Assoc 2000;284:1655–63
  • Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63:963–71
  • Berndt ER, Bir A, Busch SH, et al. The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexes. J Health Econ 2002;21: 373–96
  • Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004;22:3524–30
  • D’Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265–81
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613–9
  • Jansen AG, Sanders EA, Hoes AW, et al. Influenza- and respiratory syncytial virus-associated mortality and hospital-isations. Eur Respir J 2007 [in press]
  • Mullooly JP, Bridges CB, Thompson WW, et al. Influenza-and RSV-associated hospitalizations among adults. Vaccine 2007;25:846–55
  • Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158:1769–76
  • Vindt Holm M, Gyldmark M, Holme Hansen E. Pharmaco-economic assessment of oseltamivir in treating influenza – the case of otherwise healthy Danish adolescents and adults. Pharm World Sci 2004;26:339–45
  • Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003;139: 321–9
  • Nichol KL, Margolis KL, Wouremna J, et al. Effectiveness of influenza vaccine in the elderly. Gerontology 1996;42: 274–9
  • Nichol KL. Improving influenza vaccination rates among adults. Cleve Clin J Med 2006;73:1009–15
  • Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999–2000. J Am Geriatr Soc 2002;50:608–16
  • Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123–9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.